Azenta (AZTA) Stock Price, News & Analysis

Company Overview

Azenta, Inc. (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services. Researchers and biopharma companies rely on these capabilities for applications ranging from basic research and drug discovery to precision medicine. The company’s facility network supports high-throughput processing, quality control and regulatory compliance, addressing needs across genomics, transcriptomics and proteomics workflows.

Headquartered in Chelmsford, Massachusetts, Azenta serves a global customer base that includes pharmaceutical and biotechnology firms, academic institutions and contract research organizations. The company operates multiple facilities across North America, Europe and Asia, enabling scalable sample management and genomics projects. Its solutions are designed to support complex supply chains for cell and gene therapies, biologics development and large-scale biobanking initiatives.

Azenta completed its spin-off from Brooks Automation in February 2021, establishing itself as a standalone public company focused on the accelerating demands of life sciences research. The company is led by President and Chief Executive Officer Joseph L. Hawkins, whose leadership team continues to expand Azenta’s footprint in sample management automation and genomics services worldwide. Through ongoing investments in technology and facility capacity, Azenta aims to drive innovation in life sciences and deliver reliable, end-to-end solutions to its customers.

Key Stats

• Today's Range: $29.53 to $30.37
• 50-Day Range: $26.90 to $34.48
• 52-Week Range: $23.91 to $55.63
• Volume: 530,830 shs
• Average Volume: 664,106 shs
• Market Capitalization: $1.38 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.75
• Consensus Rating: Hold

Azenta Stock Analysis - MarketRank™

Azenta scored higher than 63% of companies evaluated by MarketBeat, and ranked 374th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Azenta has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Azenta has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 73.58%

Earnings Growth

Earnings for Azenta are expected to grow by 73.58% in the coming year, from $0.53 to $0.92 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Azenta is -12.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Azenta is -12.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Azenta has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.36% of the float of Azenta has been sold short.

Short Interest Ratio / Days to Cover

Azenta has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Azenta has recently decreased by 15.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Azenta does not currently pay a dividend.

Dividend Growth

Azenta does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.36% of the float of Azenta has been sold short.

Short Interest Ratio / Days to Cover

Azenta has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Azenta has recently decreased by 15.73%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.47

News Sentiment

Azenta has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Azenta this week, compared to 5 articles on an average week.

Search Interest

4 people have searched for AZTA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Azenta insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.62% of the stock of Azenta is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.08% of the stock of Azenta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AZTA Stock Analysis - Frequently Asked Questions

How have AZTA shares performed this year?

Azenta's stock was trading at $50.00 at the start of the year. Since then, AZTA shares have decreased by 39.7% and is now trading at $30.16.

How were Azenta's earnings last quarter?

Azenta, Inc. (NASDAQ:AZTA) released its quarterly earnings results on Tuesday, August, 5th. The company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.06. The firm's quarterly revenue was up .0% on a year-over-year basis.
Read the conference call transcript.

Who are Azenta's major shareholders?

Azenta's top institutional investors include Conestoga Capital Advisors LLC (4.19%), Allspring Global Investments Holdings LLC (2.94%), Geode Capital Management LLC (2.33%) and Palisade Capital Management LP (1.83%). Insiders that own company stock include John Marotta, David C Gray, Herman Cueto, Olga Pirogova, William L Cornog and Violetta Hughes.
View institutional ownership trends.

How do I buy shares of Azenta?

Shares of AZTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Azenta own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Azenta investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/03/2025
• Fiscal Year End: 9/30/2025
• Next Earnings (Estimated): 11/11/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Machinery
• Current Symbol: NASDAQ:AZTA
• CIK: 933974
• Web: www.brooks.com
• Phone: (978) 262-2400
• Fax: 978-262-2500
• Employees: 3,300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Azenta: $35.75
• High Price Target: $40.00
• Low Price Target: $33.00
• Potential Upside/Downside: +18.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 56.91
• P/E Growth: N/A
• Net Income: -$164.17 million
• Net Margins: -18.45%
• Pretax Margin: -26.43%
• Return on Equity: 1.35%
• Return on Assets: 1.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.76
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $656.32 million
• Price / Sales: 2.11
• Cash Flow: $4.49 per share
• Price / Cash Flow: 6.71
• Book Value: $36.51 per share
• Price / Book: 0.83

Miscellaneous

• Outstanding Shares: 45,840,000
• Free Float: 40,972,000
• Market Cap: $1.38 billion
• Optionable: Optionable
• Beta: 1.65